Kronos Bio, Inc. announced the appointment of Katherine Vega Stultz to its Board of Directors, replacing Otello Stampacchia, Ph.D., who stepped down as of March 31, 2023. Ms. Stultz has over 25 years of experience in the biopharmaceutical industry and currently serves as the President and Chief Executive Officer of Ocelot Bio. Prior to this role, Ms. Stultz served as Chief Operating Officer at Graphite Bio.

Previously, she spent 15 years at Celgene, where she held leadership roles including General Manager of Portugal and Spain; Corporate Vice President, Global Project and Portfolio Management for Hematology/Oncology; and Executive Director, Global Project Leader and U.S. Brand Leader. She began her career at Eli Lilly & Company and ConvaTec. Ms. Stultz earned her B.S. in mechanical engineering from Cornell University.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.